Skip to main content
OpenTrials
Completed

NCT Number: NCT07166497

Evaluation of the Effect of the Product RV4660C CY0203 on Clinical, Biometrological and Biological Parameters in Adults With Mild to Moderate Atopic Dermatitis, an Exploratory Study

In this exploratory study, we assessed the efficacy of a cosmetic product in adults suffering from mild to moderate atopic dermatitis. This exploratory study has been conducted as a monocentric non randomized study.

To perform this clinical study, 21 non menopausal women, aged from 18 years and older, suffering from mild to moderate atopic dermatitis were enrolled.

The subjects applied the investigational product once a day, in the evening on the whole body/ off face for up to 31 days.

4 visits were planned:

* Visit 1 - Day 1 - Inclusion visit * Visit 2 - Day 8 - Intermediate visit * Visit 3 - Day 29 (± 3 days) - Intermediate visit * Visit 4 - Day 36 (± 3 days) - End of study visit

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Mild to Moderate Atopic Dermatitis

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Skin Research Center

Toulouse, France, 31000

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Main inclusion criteria :

  • Woman 18 years or older
  • Non-menopausal woman
  • Subject with phototype I, II, III, IV as classified by Fitzpatrick
  • Subject with AD according to "The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis"
  • Mild to moderate AD with SCORAD (SCORing Atopic Dermatitis) between 20 and 40 inclusive
  • Subject who had at least 1 inflammatory AD flare-up in target areas in the year prior to inclusion visit
  • Subject with at least one measuring target area on each upper or lower limb and defined as a typical AD flare-up area in the opinion of the subject
  • Subject with at least one target area on each upper or lower limb with the following SCORAD target signs (between 3 and 18):
  • Erythema ≥ 1
  • Xerosis > 1
  • Subject with pruritus intensity ≥ 3 on SCORAD analog visual scale (VAS)

Main non-inclusion criteria:

  • Subject with superinfected AD
  • Subject with a known history of allergy or intolerance to the components of the study product
  • Subject with a dermatological condition other than AD, or characteristics (for example, tattoo) on the study areas, likely to interfere with the study evaluations according to the investigator's opinion
  • Subject with another dermatological condition, acute or chronic pathology, or history of pathology, likely to interfere with study evaluations, or considered dangerous to the subject or incompatible with study requirements, in the opinion of the investigator
  • Topical or oral treatment established or modified during the previous weeks or planned to be established or modified during the study, liable to interfere with the evaluation of the efficacy or cutaneous tolerance of the investigational product according to the investigator's assessment

Treatment and study plan

Cosmetic product RV4660C CY0203

Other

The product was applied once a day, in the evening, on the whole body/ off face on previously cleansed skin. The product was warmed in the hands before being applied in wide movements.

Primary outcomes

  1. Severity of atopic dermatitis throughout the body with SCORAD (SCOring Atopic Dermatitis)

    Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application

    Evaluation performed by the investigator of

    • The extent of the disease using the rule of nines to estimate percentage of the affected body surface area. The maximum value for the extent of the disease is 100%.
    • The disease intensity calculated based on six characteristics: erythema, edema, oozing/crusts, excoriations, lichenification, and dryness. Each characteristic is given a score between 0 and 3, where 0 is absent and 3 is severe. The scores for each characteristic are added together for a total intensity score of up to 18.

    Evaluation performed by the subject of subjective symptoms including sleep loss and pruritus using a 10 cm visual analogue scale with a total maximum score of 20.

    The SCORAD was then calculated with the following formula:

    Extent/5 + 7×Intensity/2 + Subjective Symptoms

  2. Severity of the target atopic dermatitis areas (defined as a typical AD flare-up area in the opinion of the subject) with target SCORAD

    Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application

    Evaluation performed by the investigator of severity of the target areas calculated based on six characteristics: erythema, edema, oozing/crusts, excoriations, lichenification, and dryness. Each characteristic is given a score between 0 and 3, where 0 is absent and 3 is severe. The scores for each characteristic are added together for a total intensity score of up to 18.

  3. The pruritus severity with the Chronic itch burden scale over the past 7 days

    Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application

    Evaluation performed by the subject of pruritus severity on a NRS (0=no itching to 10=worst itching imaginable) over the past 7 days

  4. The impact of pruritus on quality of life with the Chronic itch burden scale over the past 7 days

    Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application

    Evaluation performed by the subject of the impact of pruritus on daily life over the past 7 days with 20 questions from 0=not at all, 1=a little, 2=somewhat, 3=a lot and 4=very much

  5. The pruritus severity with VAS (Visual Analog Scale) over the last 72 hours

    Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application

    Evaluation performed by the subject of pruritus severity using a VAS (continuous sliding scale from 0 cm = no itching to 10 cm = worst itching imaginable) over the last 72 hours using the SCORAD scale

  6. The pruritus severity with VAS (Visual Analog Scale) over the last 24 hours

    Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application

    Evaluation performed by the subject of pruritus severity using a VAS (continuous sliding scale from 0 cm = no itching to 10 cm = worst itching imaginable) over the last 24 hours

  7. The quality of sleep using connected watch

    Time frame: Before products' application from Day 1 to Day 7 and after 21 consecutive days of products' application from Day 8 to Day 29.

    Measurement of sleep parameters using a connected watch worn on the wrist by the subjects

  8. The quality of sleep with VAS (Visual Analog Scale)

    Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application

    Evaluation performed by the subject of quality of sleep using a VAS (continuous sliding scale from 0 cm = no sleep disturbance to 10 cm = worst sleep disturbance imaginable) over the last 72 hours using the SCORAD scale

  9. The quality of sleep with the Chronic itch burden scale

    Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application

    Evaluation performed by the subject of quality of sleep using the question n°4 from the Chronic Itch Burden Scale questionnaire

  10. The quality of sleep with the Sleep Health index

    Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application

    Evaluation performed by the subject of quality of sleep using the questions n°6 to 10 from the Sleep Health index

  11. The quality of sleep using Insomnia Severity Index (ISI) questionnaire

    Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application

    Evaluation performed by the subject of the quality of sleep

  12. The scratch using a connected watch

    Time frame: Before products' application from Day 1 to Day 7 and after 21 consecutive days of products' application from Day 8 to Day 29.

    Measurement of scratch using a connected watch worn on the wrist by the subjects

  13. The skin hydration using a Corneometer

    Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application

    Evaluation of the hydration index performed by a clinical research technician on one of the target area

  14. The skin barrier condition using a Vapometer

    Time frame: Before application and before wearing the connected watch (Day 1, Visit 1), after 7 consecutive days of wearing connected watch - before application (Day 8, Visit 2), after 21 (Day 29, Visit 3) and 28 (Day 36, Visit 4) consecutive days of application

    Evaluation of the trans-epidermal water loss performed by a clinical research technician on one of the target area

  15. The skin microbiota with non-invasive skin swabs

    Time frame: Before product's application (Day 8, Visit 2) and after 28 consecutive days of product's application (Day 36, Visit 4)

    Evaluation of the skin microbiota performed by a clinical research technician on one of the target areas

  16. Metabolites produced by host and microorganisms of the skin with non-invasive skin D-Squames

    Time frame: Before product's application (Day 8, Visit 2) and after 28 consecutive days of product's application (Day 36, Visit 4)

    Evaluation of the metabolites produced by host and microorganisms of the skin performed by a clinical research technician on one of the target areas

  17. Metabolites produced by host and microorganisms of the skin with non-invasive skin swabs

    Time frame: Before product's application (Day 8, Visit 2) and after 28 consecutive days of product's application (Day 36, Visit 4)

    Evaluation of the metabolites produced by host and microorganisms of the skin performed by a clinical research technician on one of the target areas

Sponsors and collaborators

Lead sponsor

Pierre Fabre Dermo Cosmetique

Industry

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Sep 10, 2025
Registry last updated
Sep 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.